AstraZeneca Investor Presentation — September 2022

Document content

06 SEPTEMBER 2022Rare Disease

ALBIE LIVING WITH LAL -DInorder, among other things, toutilise the 'safe harbour' provisions ofthe USPrivate Securities Litigation Reform Act of1995, AstraZeneca (hereafter ‘the Group’) provides the

following cautionary statement :this document contains certain forward -looking statements with respect tothe operations, performance and financial condition ofthe Group,

including, among other things, statements about expected revenues, margins, earnings pershare orother financial orother measures .Although theGroup believes itsexpectations are

based onreasonable assumptions, any forward -looking statements, bytheir very nature, involve risks and uncertainties and may beinfluenced byfactors that could cause actual

outcomes and results tobematerially different from those predicted .The forward -looking statements reflect knowledge and information available atthedate ofpreparation ofthis

document and theGroup undertakes noobligation toupdate these forward -looking statements .The Group identifies theforward -looking statements byusing thewords 'anticipates',

'believes', 'expects', 'intends' and similar expressions insuch statements .Important factors that could cause actual results todiffer materially from those contained inforward -looking

statements, certain ofwhich arebeyond theGroup’s control, include, among other things :therisk offailure ordelay indelivery ofpipeline orlaunch ofnew medicines ;therisk of

failure tomeet regulatory orethical requirements formedicine development orapproval ;therisk offailure toobtain, defend and enforce effective IPprotection and IPchallenges by

third parties ;theimpact ofcompetitive pressures including expiry orloss ofIPrights, and generic competition ;theimpact ofprice controls and reductions ;theimpact ofeconomic,